Halozyme Therapeutics, Inc. (HALO)

NASDAQ: HALO · IEX Real-Time Price · USD
43.82
-0.10 (-0.23%)
At close: May 24, 2024, 4:00 PM
44.90
+1.08 (2.46%)
After-hours: May 24, 2024, 6:22 PM EDT
-0.23%
Market Cap 5.58B
Revenue (ttm) 862.99M
Net Income (ttm) 318.80M
Shares Out 127.27M
EPS (ttm) 2.42
PE Ratio 18.11
Forward PE 10.90
Dividend n/a
Ex-Dividend Date n/a
Volume 869,022
Open 43.65
Previous Close 43.92
Day's Range 43.82 - 43.82
52-Week Range 31.86 - 46.16
Beta 1.26
Analysts Buy
Price Target 54.00 (+23.23%)
Earnings Date May 7, 2024

About HALO

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 373
Stock Exchange NASDAQ
Ticker Symbol HALO
Full Company Profile

Financial Performance

In 2023, HALO's revenue was $829.25 million, an increase of 25.62% compared to the previous year's $660.12 million. Earnings were $281.59 million, an increase of 39.31%.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for HALO stock is "Buy." The 12-month stock price forecast is $54.0, which is an increase of 23.23% from the latest price.

Price Target
$54.0
(23.23% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®

Updated Prescription Drug User Fee Act goal date of December 29, 2024 SAN DIEGO , May 21, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myer...

7 days ago - PRNewsWire

Halozyme to Participate in Upcoming Investor Conferences

SAN DIEGO , May 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and host investor...

19 days ago - PRNewsWire

HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS

Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.79 1 Royalty Revenue Increased 21% YOY t...

20 days ago - PRNewsWire

Mahesh Krishnan Elected to Halozyme's Board of Directors

SAN DIEGO , April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors.

4 weeks ago - PRNewsWire

Halozyme to Report First Quarter 2024 Financial and Operating Results

SAN DIEGO , April 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results on Tuesday, Ma...

4 weeks ago - PRNewsWire

HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS

Reiterating 2024 Financial Guidance: Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535-585 Million, Representing YOY Growth of 26- 37% and Non-GAAP Diluted ...

3 months ago - PRNewsWire

Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results

SAN DIEGO , Feb. 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2023 financial and operating results o...

3 months ago - PRNewsWire

Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

SAN DIEGO , Jan. 29, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Takeda received European Commission (EC) approval for HYQVIA® [Immune Globulin In...

4 months ago - PRNewsWire

Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis

VYVDURA® provides patients with option for self-administration SAN DIEGO , Jan. 18, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received ap...

4 months ago - PRNewsWire

Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

SAN DIEGO , Jan. 16, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Takeda received U.S. Food and Drug Administration (FDA) approval for HYQVIA® [Imm...

4 months ago - PRNewsWire

Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types

Reduces treatment time by approximately 80% compared to standard intravenous (IV) infusion Subcutaneous (SC) injection o ffers the potential for a faster, more convenient alternative to IV infusion an...

4 months ago - PRNewsWire

Halozyme to Host Investor Business Forum and Long-Term Outlook Call

SAN DIEGO, Jan. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it will host an Investor Business Forum and Long-Term Outlook Call on Wednesday, J...

4 months ago - PRNewsWire

Halozyme to Present at Upcoming Investor Conferences

SAN DIEGO , Nov. 27, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the senior leadership team are scheduled to present and host investor ...

6 months ago - PRNewsWire

Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis

VYVGART® SC Now Approved for Subcutaneous Administration, Adding to the Already Approved IV Administration SAN DIEGO , Nov. 16, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozy...

6 months ago - PRNewsWire

HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS

Royalty Revenue Increased 15% YOY to Record $114.4 million Announces Acceleration into 2023 of Remaining $250M Share Repurchase through ASR GAAP Diluted EPS of $0.61 and Non-GAAP Diluted EPS of $0.75 ...

7 months ago - PRNewsWire

Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease

Acumen represents thirteenth license partner for ENHANZE ® Alzheimer's disease is a large and expanding market opportunity SAN DIEGO , Nov. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:...

7 months ago - PRNewsWire

Halozyme To Report Third Quarter 2023 Financial and Operating Results

SAN DIEGO , Oct. 30, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2023 financial and operating results on Monday, Nove...

7 months ago - PRNewsWire

Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma

BMS in discussions with health authorities regarding next steps for submission and approval of subcutaneous nivolumab in multiple indications SAN DIEGO , Oct. 19, 2023 /PRNewswire/ -- Halozyme Therape...

7 months ago - PRNewsWire

Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference

Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector...

8 months ago - PRNewsWire

Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery

Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector...

8 months ago - PRNewsWire

Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

First subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain Tecentriq® subcutaneous formulation with ENHANZE® reduces treatment time to seven minutes compared to 30-60 ...

9 months ago - PRNewsWire

HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS

Revenue Increased 45% YOY to $221.0 million; GAAP Diluted EPS of $0.56 and Non-GAAP Diluted EPS of $0.74 1  Royalty Revenue Increased 31% YOY to Record $111.7 million Raised 2023 Non-GAAP Diluted EPS ...

10 months ago - PRNewsWire

Halozyme To Report Second Quarter 2023 Financial and Operating Results

SAN DIEGO , July 25, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2023 financial and operating results on Tuesday, Au...

10 months ago - PRNewsWire

Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

SAN DIEGO , July 17, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx reported positive topline data from the ADHERE study evaluating VYVGART® H...

11 months ago - PRNewsWire

Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis

SAN DIEGO , July 13, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche's Phase 3 OCARINA II trial evaluating OCREVUS® (ocrelizumab) with ENHANZE® ...

11 months ago - PRNewsWire